FrancophonIA/ELRC3.0 huggingface dataset:
English: Sodium piperacillin 2.085 g sodium tazobactam 268.300 mg
Slovenian: 2g/250mg prašek za raztopino za infundiranje infuzija natrijeva sol piperacilina 2,085 g natrijeva sol tazobaktama 268,300 mg
English: Piperacillin (in the form of piperacillin sodium) 4 g Tazobactam (in the form of tazobactam sodium) 0.50 g
Slovenian: Tazocel 4/0,5 g Polvo para solución inyectable piperacilin (v obliki natrijeve soli piperacilina) 4 g in tazobaktam (v obliki natrijeve soli tazobaktama) 0,50 g
English: 2g piperacillin and 0.25g tazobactam (both present as sodium salts).
Slovenian: 2 g piperacilina in 0,25 g tazobaktama (oba v obliki natrijeve soli)
English: 2.085 g of piperacillin sodium equivalent to 2 g of piperacillin and 0.2683 g of tazobactam sodium equivalent to 250 mg of tazobactam
Slovenian: 2,085 g natrijeve soli piperacilina, ki ustreza 2 g piperacilina in 0,2683 g natrijeve soli tazobaktama, ki ustreza 250 mg tazobaktama
English: Piperacillin (in the form of piperacillin sodium) 2 g Tazobactam (in the form of tazobactam sodium) 0.25 g
Slovenian: 2/0,25 g prašek za raztopino za injiciranje piperacilin (v obliki natrijeve soli piperacilina) 2 g in tazobaktam (v obliki natrijeve soli tazobaktama) 0,25 g
English: Sodium piperacillin 4.170 g sodium tazobactam 536.600 mg
Slovenian: 4g/500mg prašek za raztopino za infundiranje infuzija natrijeva sol piperacilina 4,170 g natrijeva sol tazobaktama 536,600 mg
English: 4g piperacillin and 0.5g tazobactam (both present as sodium salts).
Slovenian: 4 g piperacilina in 0,5 g tazobaktama (oba v obliki natrijeve soli)
English: Piperacillin
Slovenian: Ciper
English: 4.17 g sodium piperacillin equivalent to 4 g piperacillin and 0.5366 g sodium tazobactam equivalent to 0.5 g tazobactam.
Slovenian: 4,17 g natrijeve soli piperacilina, ki ustreza 4 g piperacilina in 0,5366 g natrijeve soli tazobaktama, ki ustreza 0,5 g tazobaktama
English: Trockenstechampullen 4,0 g/0,5 g Lyophilisate for solution for injection or infusion
Slovenian: Tazonam 4,0 g/0,5 gTrockenstechampullen 4,0 g/0,5 g liofilizat za raztopino za injiciranje ali infundiranje
English: 4,170 g piperacillin sodium equivalent to 4000 mg of piperacillin and 0.5366 g tazobactam sodium equivalent to 500 mg of tazobactam.
Slovenian: 4,170 g natrijeve soli piperacilina, ki ustreza 4000 mg piperacilina in 0,5366 g natrijeve soli tazobaktama, ki ustreza 500 mg tazobaktama
English: Powder for solution for injection and infusion contains 2.085g piperacillin sodium equivalent to 2g piperacillin and 0.2683 g tazobactam sodium equivalent to 250 milligrams tazobactam
Slovenian: Tazocin 2,25g vsebuje 2,085 g natrijeve soli piperacilina, ki ustreza 2 g piperacilina in 0,2683 g natrijeve soli tazobaktama, ki ustreza 250 mg tazobaktama
English: 4.170 g piperacillin sodium equivalent to 4 g piperacillin and 0.5366 g tazobactam sodium equivalent to 500 mg tazobactam.
Slovenian: 4,170 g natrijeve soli piperacilina, ki ustreza 4 g piperacilina in 0,5366 g natrijeve soli tazobaktama, ki ustreza 500 mg tazobaktama
English: Sodium piperacillin and sodium tazobactam, equivalent to 2 g piperacillin and 250 mg tazobactam.
Slovenian: Tazocin® 2 g/ 250 mg 2g /250 mg prašek za raztopino za injiciranje natrijeva sol piperacilina in natrijeva sol tazobaktama, ki ustrezata 2 g piperacilina in 250 mg tazobaktama
English: 2g/250 mg Powder for Solution for Injection or Infusion
Slovenian: 2g/250 mg prašek za raztopino za injiciranje
English: Piperacillin sodium corresponding to piperacillin 2 g and tazobactam sodium corresponding to tazobactam 0,25 g
Slovenian: 1324 Lysaker Norveška natrijeva sol piperacilina, ki ustreza 2 g piperacilina, natrijeva sol tazobaktama, ki ustreza 0,25 g tazobaktama
English: This overview was last updated in 05-2018.
Slovenian: Pregled je bil nazadnje posodobljen 05-2018.
English: Further information on Ivemend can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Več informacij o zdravilu Ivemend je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Ivemend?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ivemend?
English: This means that it is converted to aprepitant in the body.
Slovenian: To pomeni, da se šele v telesu pretvori v aprepitant.
English: Aprepitant has been authorised in the European Union (EU) as Emend since 2003.
Slovenian: Aprepitant je v Evropski uniji (EU) odobren od leta 2003 kot zdravilo Emend.
English: What benefits of Ivemend have been shown in studies?
Slovenian: Kakšne koristi zdravila Ivemend so se pokazale v študijah?
English: The European Medicines Agency therefore decided that Ivemend's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Ivemend večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: What is Ivemend and what is it used for?
Slovenian: Kaj je zdravilo Ivemend in za kaj se uporablja?
English: Ivemend received a marketing authorisation valid throughout the EU on 11 January 2008.
Slovenian: Za zdravilo Ivemend je bilo 11. januarja 2008 izdano dovoljenje za promet, veljavno po vsej EU.
English: Other information about Ivemend
Slovenian: Druge informacije o zdravilu Ivemend
English: Why is Ivemend authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Ivemend odobreno v EU?
English: An overview of Ivemend and why it is authorised in the EU
Slovenian: Pregled zdravila Ivemend in zakaj je odobreno v EU
English: In children it may be given on the first day or on multiple days through a tube inserted into a large vein near the heart.
Slovenian: Pri otrocih se lahko daje prvi dan ali več dni zapored po cevki, vstavljeni v veliko veno blizu srca.
English: As for all medicines, data on the use of Ivemend are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Ivemend stalno spremljajo.
English: What are the risks associated with Ivemend?
Slovenian: Kakšna tveganja so povezana z zdravilom Ivemend?
English: It contains the active substance fosaprepitant.
Slovenian: Vsebuje učinkovino fosaprepitant.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ivemend have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ivemend upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Aprepitant is a neurokinin 1 (NK1) receptor antagonist.
Slovenian: Aprepitant je zaviralec receptorjev za nevrokinin 1 (NK1).
English: Side effects reported with Ivemend are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Ivemend, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: It is used in adults and children from 6 months of age who are undergoing chemotherapy known to cause moderate or severe nausea and vomiting.
Slovenian: Uporablja se pri odraslih in otrocih od šestega meseca starosti naprej, ki prejemajo kemoterapijo, za katero je znano, da povzroča zmerno ali hudo slabost in bruhanje.
English: For more information about using Ivemend, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Ivemend glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: The most common side effects with Ivemend (seen in between 1 and 10 patients in 100) are increased liver enzymes, headache, hiccups, constipation, dyspepsia (heartburn), loss of appetite and fatigue (weakness or tiredness).
Slovenian: Najpogostejši neželeni učinki zdravila Ivemend (ki se pojavijo pri 1 do 10 bolnikih od 100) so zvišane ravni jetrnih encimov, glavobol, kolcanje, zaprtost, dispepsija (zgaga), izguba teka in izčrpanost (šibkost ali utrujenost).
English: Ivemend must not be used at the same time as pimozide (used to treat mental illness), terfenadine and astemizole (used to treat allergy symptoms) and cisapride (used to relieve certain stomach problems).
Slovenian: Zdravilo Ivemend se ne sme uporabljati sočasno s pimozidom (uporablja se za zdravljenje duševnih bolezni), terfenadinom in astemizolom (uporabljata se za zdravljenje simptomov alergije) ter cisapridom (uporablja se za lajšanje nekaterih težav z želodcem).
English: It stops a chemical in the body called ‘substance P' from attaching to the NK1 receptors.
Slovenian: Preprečuje, da bi se kemična snov v telesu (snov P) vezala na receptorje za NK1.
English: When substance P attaches to these receptors, it causes nausea and vomiting.
Slovenian: Če se snov P veže na te receptorje, to povzroči slabost in bruhanje.
English: In adults, Ivemend is given as a slow infusion into a vein on the first day of chemotherapy.
Slovenian: Pri odraslih se zdravilo Ivemend daje s počasnim infundiranjem v veno prvi dan kemoterapije.
English: The active substance in Ivemend, fosaprepitant, is a ‘prodrug' of aprepitant.
Slovenian: Učinkovina v zdravilu Ivemend, fosaprepitant, je „predzdravilo“ aprepitanta.
English: How is Ivemend used?
Slovenian: Kako se zdravilo Ivemend uporablja?
English: A main study in 2,000 patients with cancer showed that Ivemend was as effective as a Emend another medicine approved for preventing nausea and vomiting.
Slovenian: Glavna študija z 2 000 bolniki z rakom je pokazala, da je zdravilo Ivemend enako učinkovito kot zdravilo Emend, drugo zdravilo za preprečevanje slabosti in bruhanja.
English: Ivemend is a medicine for preventing nausea (feeling sick) and vomiting caused by chemotherapy cancer medicines.
Slovenian: Ivemend je zdravilo za preprečevanje navzeje (slabosti) in bruhanja, ki ju povzročajo kemoterapevtska zdravila za zdravljenje raka.
English: Ivemend must always be given together with other medicines that prevent nausea and vomiting, including a corticosteroid (such as dexamethasone) and a ‘5HT3 antagonist' (such as ondansetron).
Slovenian: Zdravilo Ivemend je treba jemati z drugimi zdravili za preprečevanje slabosti in bruhanja, vključno s kortikosteroidom (kot je deksametazon) in antagonistom 5-HT3 (kot je ondansetron).
English: By blocking these receptors, Ivemend can prevent nausea and vomiting, which often happens during and after chemotherapy.
Slovenian: Zdravilo Ivemend z zaviranjem teh receptorjev prepreči slabost in bruhanje, ki se pogosto pojavita med kemoterapijo in po njej.
English: Around 72% of patients treated with either medicine did not have any nausea or vomiting over the five days after receiving chemotherapy.
Slovenian: V petih dneh po prejemu kemoterapije se slabost in bruhanje nista pokazala pri približno 72 % bolnikov, zdravljenih z enim ali drugim zdravilom.
English: A main study showed that Ivemend was as effective as Emend at preventing nausea and vomiting in patients undergoing chemotherapy and its side effects are considered to be manageable.
Slovenian: Glavna študija je pokazala, da je zdravilo Ivemend pri preprečevanju slabosti in bruhanja pri bolnikih, ki prejemajo kemoterapijo, enako učinkovito kot zdravilo Emend, njegovi neželeni učinki pa so obvladljivi.
English: For the full list of side effects reported with Ivemend, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Ivemend, glejte navodilo za uporabo.
English: How does Ivemend work?
Slovenian: Kako zdravilo Ivemend deluje?
English: _ _ 1 Whole virion non-adjuvanted influenza vaccine, inactivated, containing antigen of *: A/Vietnam/1203/2004 (H5N1) 7.5 micrograms** per 0.5 ml dose * propagated in Vero cells (continuous cell line of mammalian origin) ** expressed in micrograms hemagglutinin
Slovenian: _ _ 1 Cepivo proti gripi s celimi inaktiviranimi virioni brez adjuvansa, ki vsebuje antigen *: A/Vietnam/1203/2004 (H5N1) 7,5 mikrogramov** na odmerek 0,5 ml * razmnožen v celicah Vero (neprekinjena celična linija sesalskega izvora) ** izraženo v mikrogramih hemaglutinina
English: 20 vials
Slovenian: 20 vial
English: 1 syringe
Slovenian: 1 brizga
English: Immediate Packaging Content (concentration)
Slovenian: Vsebina (koncentracija)
English: Pack size multi-dose vial (glass)
Slovenian: Večodmerna viala (steklena)
English: Single-dose prefilled syringe (glass) without needle
Slovenian: Enoodmerna napolnjena injekcijska brizga (steklena) brez igle
English: MA (EU) Number (Invented) name
Slovenian: Številka EU
English: Route of Administration
Slovenian: Pot uporabe Stična ovojnina
English: This overview was last updated in 05-2019.
Slovenian: Povzetek je bil nazadnje posodobljen 05-2019.
English: Further information on Telzir can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Telzir.
Slovenian: Nadaljnje informacije za zdravilo Telzir so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Telzir.
English: Telzir tablets can be taken with or without food.
Slovenian: Tablete zdravila Telzir se lahko vzamejo s hrano ali brez nje.
English: It contains the active substance fosamprenavir.
Slovenian: Vsebuje učinkovino fosamprenavir.
English: Telzir received a marketing authorisation valid throughout the EU on 12 July 2004.
Slovenian: Za zdravilo Telzir je bilo 12. julija 2004 izdano dovoljenje za promet, veljavno po vsej EU.
English: Telzir has been studied in three main studies involving 1,862 adults.
Slovenian: Zdravilo Telzir so proučevali v treh glavnih študijah, v katere je bilo vključenih 1 862 odraslih.
English: A similar benefit was also seen in one main study including 57 children aged between 2 and 18 years.
Slovenian: Podobno učinkovitost so opazili tudi v eni glavni študiji, ki je vključevala 57 otrok, starih od dveh do 18 let.
English: What measures are being taken to ensure the safe and effective use of Telzir?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Telzir?
English: Similar side effects are seen in younger patients.
Slovenian: Pri mlajših bolnikih so opaženi podobni neželeni učinki.
English: In adults, each dose of Telzir must be given with 100 mg ritonavir, twice a day.
Slovenian: Odrasli morajo vsak odmerek zdravila Telzir vzeti skupaj s 100 mg ritonavirja dvakrat na dan.
English: However, there were too few patients aged below 6 years to support the use of Telzir in this age group.
Slovenian: Vendar je bilo bolnikov, mlajših od šest let, premalo, da bi bila potrjena uporaba zdravila Telzir v tej starostni skupini.
English: An overview of Telzir and why it is authorised in the EU
Slovenian: Pregled zdravila Telzir in zakaj je odobreno v EU
English: As for all medicines, data on the use of Telzir are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Telzir stalno spremljajo.
English: Telzir is available as tablets (700 mg) and as an oral suspension (50 mg/ml) to be taken by mouth.
Slovenian: Zdravilo Telzir je na voljo v obliki tablet (700 mg) in kot peroralna suspenzija (50 mg/ml) za peroralno uporabo.
English: In younger patients, the dose of ritonavir depends on body weight.
Slovenian: Pri mlajših bolnikih je odmerek ritonavirja odvisen od njihove telesne mase.
English: For more information about using Telzir, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Telzir glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Why is Telzir authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Telzir odobreno v EU?
English: As Telzir is converted into amprenavir in the body, it must not be given at the same time as other medicines containing amprenavir.
Slovenian: Ker se zdravilo Telzir v telesu pretvori v amprenavir, se ne sme dajati istočasno z drugimi zdravili, ki vsebujejo amprenavir.
English: Telzir, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Slovenian: Zdravilo Telzir v kombinaciji z drugimi protivirusnimi zdravili zniža količino virusa HIV v krvi in jo vzdržuje na nizki ravni.
English: What are the risks associated with Telzir?
Slovenian: Kakšna tveganja so povezana z zdravilom Telzir?
English: Telzir is an antiviral medicine for treating patients aged 6 years or above who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Slovenian: Telzir je protivirusno zdravilo za zdravljenje bolnikov, starejših od šest let, ki so okuženi z virusom človeške imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
English: What benefits of Telzir have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Telzir izkazalo v študijah?
English: Side effects reported with Telzir are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Telzir, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: The oral suspension should be taken without food in adults, but in younger patients it should be taken with food in order to hide the taste and help them stick to treatment.
Slovenian: Odrasli naj peroralno suspenzijo jemljejo brez hrane, mlajši bolniki pa naj jo vzamejo s hrano, da se prikrije njen okus in se jim pomaga, da se držijo režima zdravljenja.
English: In one study, after 48 weeks of treatment, 69% of previously untreated adults taking ritonavir-boosted Telzir (221 out of 322) and 68% of those taking nelfinavir (221 out of 327) had viral loads below 400 copies/ml (considered a low viral load).
Slovenian: V eni študiji je po 48 tednih zdravljenja imelo 69 % (221 od 322) predhodno nezdravljenih bolnikov, ki so jemali z ritonavirjem ojačano zdravilo Telzir, in 68 % (221 od 327) bolnikov, ki so jemali nelfinavir, virusno breme pod 400 kopij/ml (kar velja za nizko virusno breme).
English: What is Telzir and what is it used for?
Slovenian: Kaj je zdravilo Telzir in za kaj se uporablja?
English: Telzir must not be used in patients who are taking lurasidone (for schizophrenia and bipolar disorder), paritaprevir (for hepatitis C), simvastatin or lovastatin (for lowering blood cholesterol), rifampicin (for tuberculosis), St John's wort (a herbal preparation for depression and anxiety), or certain medicines that are broken down in the same way as Telzir or ritonavir as Telzir may affect their blood levels.
Slovenian: Zdravila Telzir ne smejo uporabljati bolniki, ki jemljejo lurazidon (za zdravljenje shizofrenije in bipolarne motnje), paritaprevir (za zdravljenje okužbe z virusom hepatitisa C), simvastatin ali lovastatin (za znižanje ravni holesterola v krvi), rifampicin (za zdravljenje tuberkuloze), šentjanževko (rastlinski pripravek za zdravljenje depresije in tesnobe) ali določena zdravila, ki se presnavljajo enako kot zdravilo Telzir ali ritonavir, saj lahko zdravilo Telzir vpliva na njihovo koncentracijo v krvi.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Telzir have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Telzir upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: The recommended dose for adults (aged 18 years or over) and for patients aged between 6 and 18 years who weigh more than 39 kg is 700 mg twice a day.
Slovenian: Priporočeni odmerek za odrasle (starejše od 18 let) in za bolnike, stare od šest do 18 let, ki tehtajo več kot 39 kg, je 700 mg dvakrat na dan.
English: Telzir does not cure HIV infection or AIDS, but it can hold off the damage to the immune system and the development of infections and diseases associated with AIDS.
Slovenian: Zdravilo Telzir ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z aidsom.
English: In patients aged between 6 and 18 years who weigh between 25 and 39 kg, the dose depends on body weight.
Slovenian: Pri bolnikih, starih od šest do 18 let, ki tehtajo med 25 in 39 kg, je odmerek odvisen od njihove telesne mase.
English: Other information about Telzir:
Slovenian: Druge informacije o zdravilu Telzir
English: For patients who have taken medicines to treat their HIV infection before and did not respond to that treatment, doctors should only prescribe Telzir once they have looked at the antiviral medicines the patient has taken before and assessed the likelihood of the virus's response to any new antiviral medicines that might be prescribed.
Slovenian: Pri bolnikih, ki so že jemali zdravila za zdravljenje okužbe z virusom HIV, a se na to vrsto zdravljenja niso odzvali, lahko zdravniki predpišejo zdravilo Telzir šele, ko pregledajo, katera protivirusna zdravila je bolnik jemal pred tem in ocenijo, kakšna je verjetnost, da se bo virus odzval na zdravljenje z novimi protivirusnimi zdravili, ki jih nameravajo predpisati.
English: Although the Agency noted that the use of ritonavir-boosted Telzir had not been studied sufficiently in heavily pretreated patients and that studies carried out in children did not compare Telzir with a comparator medicine, it decided that Telzir's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Čeprav je ugotovila, da uporaba zdravila Telzir, ojačanega z ritonavirjem, ni bila zadostno proučena pri bolnikih, ki so predhodno prejemali že več drugih zdravljenj, in da študije, opravljene pri otrocih, niso primerjale zdravila Telzir s primerjalnim zdravilom, je menila, da so koristi zdravila Telzir večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: When the enzyme is blocked, the virus does not reproduce normally, slowing down the spread of infection.
Slovenian: Zaradi zaviranja tega encima se virus ne more več normalno razmnoževati, kar zmanjša hitrost širjenja okužbe.
English: In a third study in patients who had been treated before, Telzir was less effective than the comparator medicine lopinavir, with patients taking lopinavir having larger reductions in viral loads over the first 48 weeks.
Slovenian: V tretji študiji pri bolnikih, ki so se pred tem že zdravili, je bilo zdravilo Telzir manj učinkovito od primerjalnega zdravila lopinavir, pri čemer je pri bolnikih, ki so jemali lopinavir, prišlo do večjega zmanjšanja virusnega bremena v prvi 48 tednih zdravljenja.
English: Treatment with Telzir should be started by a doctor who has experience in the management of HIV infection.
Slovenian: Zdravljenje z zdravilom Telzir lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
English: The European Medicines Agency concluded that Telzir, which contains a prodrug of amprenavir, is as effective as comparator medicines in reducing viral load.
Slovenian: Evropska agencija za zdravila je zaključila, da je zdravilo Telzir, ki vsebuje predzdravilo amprenavirja, pri zmanjševanju virusnega bremena enako učinkovito kot primerjalna zdravila.
English: The active substance in Telzir, fosamprenavir, is a ‘prodrug' of the protease inhibitor amprenavir, which means that it is converted into amprenavir in the body.
Slovenian: Učinkovina zdravila Telzir, fosamprenavir, je „predzdravilo“ zaviralca proteaze amprenavirja, kar pomeni, da se v telesu pretvori v amprenavir.
English: Telzir should not be used in people who are hypersensitive (allergic) to fosamprenavir, amprenavir, any of the other ingredients, or ritonavir.
Slovenian: Zdravila Telzir ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) fosamprenavir, amprenavir ali katero koli drugo sestavino zdravila ali ritonavir.